CL2018003114A1 - Compuesto fenólico y combinación del mismo con una benzodiazepina fusionada a 1,4-dihidropiridina para el tratamiento de afecciones del sistema nervioso central y vascular. - Google Patents
Compuesto fenólico y combinación del mismo con una benzodiazepina fusionada a 1,4-dihidropiridina para el tratamiento de afecciones del sistema nervioso central y vascular.Info
- Publication number
- CL2018003114A1 CL2018003114A1 CL2018003114A CL2018003114A CL2018003114A1 CL 2018003114 A1 CL2018003114 A1 CL 2018003114A1 CL 2018003114 A CL2018003114 A CL 2018003114A CL 2018003114 A CL2018003114 A CL 2018003114A CL 2018003114 A1 CL2018003114 A1 CL 2018003114A1
- Authority
- CL
- Chile
- Prior art keywords
- central
- treatment
- nervous system
- dihydropyridine
- benzodiazepine
- Prior art date
Links
- 210000000653 nervous system Anatomy 0.000 title abstract 2
- 150000002989 phenols Chemical class 0.000 title abstract 2
- 230000002792 vascular Effects 0.000 title abstract 2
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 title 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 title 1
- 229940049706 benzodiazepine Drugs 0.000 title 1
- 108090000312 Calcium Channels Proteins 0.000 abstract 1
- 102000003922 Calcium Channels Human genes 0.000 abstract 1
- 230000002424 anti-apoptotic effect Effects 0.000 abstract 1
- 230000001910 anti-glutamatergic effect Effects 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 239000003963 antioxidant agent Substances 0.000 abstract 1
- 230000003078 antioxidant effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000003371 gabaergic effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000008442 polyphenolic compounds Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
- C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physiology (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU2016000059A CU24576B1 (es) | 2016-05-04 | 2016-05-04 | Compuesto fenólico y combinación del mismo con una benzodiazepina fusionada a 1,4-dihidropiridina para el tratamiento de afecciones del sistema nervioso central y vascular |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2018003114A1 true CL2018003114A1 (es) | 2019-06-14 |
Family
ID=60202803
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018003114A CL2018003114A1 (es) | 2016-05-04 | 2018-10-31 | Compuesto fenólico y combinación del mismo con una benzodiazepina fusionada a 1,4-dihidropiridina para el tratamiento de afecciones del sistema nervioso central y vascular. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US10722491B2 (https=) |
| EP (1) | EP3453704B1 (https=) |
| JP (1) | JP6997995B2 (https=) |
| KR (1) | KR102416478B1 (https=) |
| CN (1) | CN109476627B (https=) |
| AR (1) | AR108370A1 (https=) |
| AU (1) | AU2017259749C1 (https=) |
| BR (1) | BR112018072579B1 (https=) |
| CA (1) | CA3023073C (https=) |
| CL (1) | CL2018003114A1 (https=) |
| CO (1) | CO2018011927A2 (https=) |
| CU (1) | CU24576B1 (https=) |
| EA (1) | EA037951B1 (https=) |
| ES (1) | ES2878579T3 (https=) |
| MX (1) | MX384967B (https=) |
| PH (1) | PH12018502327A1 (https=) |
| SG (1) | SG11201809843SA (https=) |
| WO (1) | WO2017190714A1 (https=) |
| ZA (1) | ZA201808161B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU20160058A7 (es) | 2016-05-04 | 2017-12-08 | Centro De Investigación Y Desarrollo De Medicamentos (Cidem) Organizacion Superior De Desarrollo Emp | Derivado de benzodiazepina con actividad sobre el sistema nervioso central y vascular |
| US12324567B2 (en) * | 2018-10-16 | 2025-06-10 | Saban Ventures Pty Limited | Apparatus and method for cleaning a medical device |
| CU20190114A7 (es) | 2019-12-26 | 2021-08-06 | Centro De Investig Y Desarrollo De Medicamentos Cidem | Combinación para simultáneamente incrementar la eficacia analgésica de la morfina y reducir su dependencia física |
| CA3164091A1 (en) * | 2019-12-26 | 2021-07-15 | Centro De Investigacion Y Desarrollo De Medicamentos Cidem | Use of a benzodiazepine derivative and method of treatment of traumatic brain injury |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5281714A (en) | 1990-08-16 | 1994-01-25 | American Home Products Corporation | N,N',N'-trisubstituted-5-bisaminomethylene-1,3-dioxane-4,6-dione inhibitors of acyl-CoA: cholesterol-acyl transferase |
| MX9204939A (es) | 1991-09-06 | 1993-03-01 | American Home Prod | Inhibidores 5-bis-aminometilen-1,3-dioxan-4,6-diona n,n',n'-trisubstituidas, de la acil coenzima a: colesterol-aciltransferasa. |
| DK0578849T3 (da) | 1992-07-17 | 1995-09-18 | Biogal Gyogyszergyar | Fremgangsmåde til fremstilling af 1,3-dioxan-4, 6-dionderivater |
| JPH11180975A (ja) | 1997-10-13 | 1999-07-06 | Chemiprokasei Kaisha Ltd | アミノメチレンジオキサン誘導体、その製造方法および用途 |
| CA2558585C (en) | 2004-02-27 | 2010-10-12 | Amgen Inc. | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders |
| JP2007063444A (ja) * | 2005-08-31 | 2007-03-15 | Tdk Corp | 錯化合物及びこれを用いた光記録媒体 |
-
2016
- 2016-05-04 CU CU2016000059A patent/CU24576B1/es unknown
-
2017
- 2017-05-03 MX MX2018013422A patent/MX384967B/es unknown
- 2017-05-03 EA EA201892462A patent/EA037951B1/ru unknown
- 2017-05-03 SG SG11201809843SA patent/SG11201809843SA/en unknown
- 2017-05-03 WO PCT/CU2017/050003 patent/WO2017190714A1/es not_active Ceased
- 2017-05-03 AU AU2017259749A patent/AU2017259749C1/en not_active Ceased
- 2017-05-03 BR BR112018072579-0A patent/BR112018072579B1/pt not_active IP Right Cessation
- 2017-05-03 ES ES17732730T patent/ES2878579T3/es active Active
- 2017-05-03 CA CA3023073A patent/CA3023073C/en active Active
- 2017-05-03 JP JP2019510749A patent/JP6997995B2/ja not_active Expired - Fee Related
- 2017-05-03 EP EP17732730.1A patent/EP3453704B1/en active Active
- 2017-05-03 US US16/098,683 patent/US10722491B2/en not_active Expired - Fee Related
- 2017-05-03 KR KR1020187035042A patent/KR102416478B1/ko not_active Expired - Fee Related
- 2017-05-03 CN CN201780040492.9A patent/CN109476627B/zh not_active Expired - Fee Related
- 2017-05-04 AR ARP170101153A patent/AR108370A1/es unknown
-
2018
- 2018-10-31 CL CL2018003114A patent/CL2018003114A1/es unknown
- 2018-11-02 CO CONC2018/0011927A patent/CO2018011927A2/es unknown
- 2018-11-05 PH PH12018502327A patent/PH12018502327A1/en unknown
- 2018-12-03 ZA ZA2018/08161A patent/ZA201808161B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX384967B (es) | 2025-03-14 |
| CU24576B1 (es) | 2022-02-04 |
| CA3023073C (en) | 2022-08-30 |
| BR112018072579A2 (pt) | 2019-02-19 |
| KR102416478B1 (ko) | 2022-07-04 |
| CA3023073A1 (en) | 2017-11-09 |
| EP3453704B1 (en) | 2021-06-16 |
| ES2878579T3 (es) | 2021-11-19 |
| KR20210025138A (ko) | 2021-03-09 |
| JP6997995B2 (ja) | 2022-02-04 |
| CU20160059A7 (es) | 2017-12-08 |
| WO2017190714A1 (es) | 2017-11-09 |
| BR112018072579B1 (pt) | 2024-02-20 |
| JP2019516791A (ja) | 2019-06-20 |
| AR108370A1 (es) | 2018-08-15 |
| ZA201808161B (en) | 2021-10-27 |
| EA201892462A1 (ru) | 2019-07-31 |
| US20190133996A1 (en) | 2019-05-09 |
| AU2017259749A1 (en) | 2018-12-20 |
| EA037951B1 (ru) | 2021-06-11 |
| PH12018502327A1 (en) | 2019-09-02 |
| CN109476627A (zh) | 2019-03-15 |
| CO2018011927A2 (es) | 2019-02-08 |
| CN109476627B (zh) | 2021-06-15 |
| US10722491B2 (en) | 2020-07-28 |
| AU2017259749B2 (en) | 2021-08-19 |
| SG11201809843SA (en) | 2018-12-28 |
| MX2018013422A (es) | 2019-08-16 |
| EP3453704A1 (en) | 2019-03-13 |
| AU2017259749C1 (en) | 2021-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020000501A1 (es) | Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos. | |
| SV2018005750A (es) | Derivados de compuestos de indol sustituidos como inhibidores de la replicacion virica del dengue | |
| CL2018003114A1 (es) | Compuesto fenólico y combinación del mismo con una benzodiazepina fusionada a 1,4-dihidropiridina para el tratamiento de afecciones del sistema nervioso central y vascular. | |
| CO2019000386A2 (es) | Compuestos heterocíclicos como inmunomoduladores | |
| MA48987A (fr) | Dérivés d'indoline substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue | |
| CL2018002758A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue. | |
| MX2022005160A (es) | Oxisteroles y metodos de uso de los mismos. | |
| MA48943A (fr) | Dérivés d'indoline substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue | |
| CL2016002148A1 (es) | Derivados de fenilen-1,5-diamina 2,4-disustituidos y aplicaciones de los mismos, y composiciones farmacéuticas y composiciones farmacéuticamente aceptables preparadas a partir de los mismos. | |
| CL2018000292A1 (es) | Compuestos farmacéuticos | |
| MA44498A (fr) | Dérivés d'indoline substituée utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue | |
| CL2017002817A1 (es) | Derivados de indol mono o disustituidos como inhibidores de la replicación viral del dengue | |
| EA201891494A1 (ru) | Гетероциклические соединения в качестве иммуномодуляторов | |
| CL2018002729A1 (es) | Derivados de indol sustituidos como inhibidores de la replicación vírica del dengue. | |
| CL2019003309A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue. | |
| CL2017000782A1 (es) | Derivados de indol mono- o disustituidos como inhibidores de la replicación del virus del dengue | |
| UY40872A (es) | Compuestos tricíclicos fusionados de piridazinona útiles para tratar infecciones de orthomyxovirus | |
| CL2017000742A1 (es) | Indoles mono o disustituidos como inhibidores de la replicación del virus del dengue | |
| CL2017001073A1 (es) | 2,4 diamino-quinolia sustituido como nuevos agentes anticancerigenos | |
| MA41341A (fr) | Dérivés indole utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue | |
| CL2019002583A1 (es) | Inhibidores duales de magl y faah. | |
| EA201991196A1 (ru) | Претерпевшие самосборку диблок-сополимеры, состоящие из pegmema и несущих лекарственное средство полимерных сегментов | |
| MX2017009849A (es) | Composiciones de profármaco de monometilfumarato. | |
| MX393915B (es) | Nuevas formulaciones orales de belinostat. | |
| ECSP066558A (es) | Metodos y composiciones para la inhibicion de selectina |